JP2024502990A - 吸入可能なイマチニブ製剤 - Google Patents

吸入可能なイマチニブ製剤 Download PDF

Info

Publication number
JP2024502990A
JP2024502990A JP2023541251A JP2023541251A JP2024502990A JP 2024502990 A JP2024502990 A JP 2024502990A JP 2023541251 A JP2023541251 A JP 2023541251A JP 2023541251 A JP2023541251 A JP 2023541251A JP 2024502990 A JP2024502990 A JP 2024502990A
Authority
JP
Japan
Prior art keywords
cyclodextrin
acid
centipoise
pharmaceutical composition
imatinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502990A5 (enExample
Inventor
シューラー，カルロス
ヒューリー，マイケル・レアード
コロン，グレース・イー
ウィースト，ブライアン
Original Assignee
インカーダ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インカーダ セラピューティクス， インコーポレイテッド filed Critical インカーダ セラピューティクス， インコーポレイテッド
Publication of JP2024502990A publication Critical patent/JP2024502990A/ja
Publication of JP2024502990A5 publication Critical patent/JP2024502990A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023541251A 2021-01-06 2022-01-06 吸入可能なイマチニブ製剤 Pending JP2024502990A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163134336P 2021-01-06 2021-01-06
US63/134,336 2021-01-06
US202163170246P 2021-04-02 2021-04-02
US63/170,246 2021-04-02
PCT/US2022/011448 WO2022150483A1 (en) 2021-01-06 2022-01-06 Inhalable imatinib formulation

Publications (2)

Publication Number Publication Date
JP2024502990A true JP2024502990A (ja) 2024-01-24
JP2024502990A5 JP2024502990A5 (enExample) 2025-01-15

Family

ID=82357645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541251A Pending JP2024502990A (ja) 2021-01-06 2022-01-06 吸入可能なイマチニブ製剤

Country Status (6)

Country Link
US (1) US20220241278A1 (enExample)
EP (1) EP4274577A4 (enExample)
JP (1) JP2024502990A (enExample)
AU (1) AU2022205940A1 (enExample)
CA (1) CA3204054A1 (enExample)
WO (1) WO2022150483A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4311539A1 (en) * 2022-07-29 2024-01-31 Artorange Ltd. Imatinib formulation for parenteral administration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
PL2305263T3 (pl) * 2007-06-07 2012-12-31 Novartis Ag Stabilizowane amorficzne formy mesylanu imatinibu
CN102008734A (zh) * 2010-12-02 2011-04-13 深圳海王药业有限公司 一种α晶型伊马替尼的包合物及其制备方法
JP6280546B2 (ja) * 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
EP3782604A1 (en) * 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US20200360477A1 (en) * 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations for kinase inhibition

Also Published As

Publication number Publication date
US20220241278A1 (en) 2022-08-04
EP4274577A1 (en) 2023-11-15
AU2022205940A1 (en) 2023-07-20
AU2022205940A9 (en) 2024-07-18
WO2022150483A1 (en) 2022-07-14
CA3204054A1 (en) 2022-07-14
EP4274577A4 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
RU2363449C2 (ru) Водный аэрозольный препарат
US9895386B2 (en) Antibiotic formulations, unit doses, kits, and methods
US20090025713A1 (en) Nebulised Antibiotics for Inhalation Therapy
WO2010128111A1 (en) Concentrated mast cell stabilizing pharmaceutical formulations
EP2618816A2 (en) Aerosol composition for administering drugs
KR102491733B1 (ko) 항부정맥 제제
US20150034087A1 (en) Low Dose Pharmaceutical Composition Comprising Zanamivir
JP2024502990A (ja) 吸入可能なイマチニブ製剤
CN103153315A (zh) 用吸入地纽福索治疗囊性纤维化的方法
DK2704724T3 (en) Improved suspension formulation of beclomethasone dipropionate for administration by inhalation
CN116897045A (zh) 可吸入伊马替尼制剂
US20260007666A1 (en) Inhalable imatinib formulation
TWI762449B (zh) 噴霧器用組成物
US20250332152A1 (en) Inhaled therapy for cardiac arrhythmia
AU2013206401B2 (en) Antibiotic formulations, unit doses, kits, and methods
Wang et al. Materials Today Bio

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260204